D
David Slosky
Researcher at Vanderbilt University Medical Center
Publications - 22
Citations - 1934
David Slosky is an academic researcher from Vanderbilt University Medical Center. The author has contributed to research in topics: Internal medicine & Amyloidosis. The author has an hindex of 8, co-authored 18 publications receiving 1369 citations. Previous affiliations of David Slosky include Vanderbilt University.
Papers
More filters
Journal ArticleDOI
Fulminant Myocarditis with Combination Immune Checkpoint Blockade
Douglas B. Johnson,Justin M. Balko,Margaret L. Compton,Spyridon Chalkias,Joshua M. Gorham,Yaomin Xu,Mellissa Hicks,Igor Puzanov,Matthew R Alexander,Tyler L. Bloomer,Jason R Becker,David Slosky,Elizabeth J. Phillips,Mark A. Pilkinton,Laura Deeanne Craig-Owens,Nina Kola,Gregory E. Plautz,Daniel Reshef,Jonathan S. Deutsch,Raquel P. Deering,Benjamin A. Olenchock,Andrew H. Lichtman,Dan M. Roden,Christine E. Seidman,Christine E. Seidman,Igor J. Koralnik,Jonathan G. Seidman,Robert D. Hoffman,Janis M. Taube,Luis A. Diaz,Robert A. Anders,Jeffrey A. Sosman,Javid Moslehi +32 more
TL;DR: Patients with melanoma in whom fatal myocarditis developed after treatment with ipilimumab and nivolumab were having a rare, potentially fatal, T-cell-driven drug reaction, according to Pharmacovigilance studies.
Journal ArticleDOI
Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma.
Robert F. Cornell,Bonnie Ky,Brendan M. Weiss,Cherie N. Dahm,Deepak K. Gupta,Liping Du,Joseph R. Carver,Adam D. Cohen,Brian G. Engelhardt,Alfred L. Garfall,Stacey Goodman,Shelton L. Harrell,Adetola A. Kassim,Trafina Jadhav,Madan Jagasia,Javid Moslehi,Rupal O'Quinn,Michael R. Savona,David Slosky,Amanda M. Smith,Edward A. Stadtmauer,Dan T. Vogl,Adam Waxman,Daniel J. Lenihan +23 more
TL;DR: Natriuretic peptides were highly predictive of CVAEs during PI therapy for relapsed MM, especially with carfilzomib, particularly within the first 3 months of therapy, but validation of this finding is necessary before uniform incorporation into the routine management of patients receiving carfilZomib.
Journal ArticleDOI
Bisphosphonates Inhibit Osteosarcoma-Mediated Osteolysis Via Attenuation of Tumor Expression of MCP-1 and RANKL
Tetsuro Ohba,Heather A. Cole,Justin M M Cates,David Slosky,Hirotaka Haro,Takashi Ando,Herbert S. Schwartz,Jonathan G. Schoenecker +7 more
TL;DR: It is established that osteosarcoma growth directly correlates with tumor‐induced osteolysis and activation of osteoclasts in vivo, and ZOL administration directly attenuates osteosARcoma production of RANKL/MCP‐1, reducing tumor‐ induced bone destruction.
Journal ArticleDOI
Autocrine VEGF/VEGFR1 Signaling in a Subpopulation of Cells Associates with Aggressive Osteosarcoma
Tetsuro Ohba,Justin M M Cates,Heather A. Cole,David Slosky,Hirotaka Haro,Takashi Ando,Herbert S. Schwartz,Jonathan G. Schoenecker +7 more
TL;DR: It is suggested that autocrine VEGF/VEGFR1 signaling in a subpopulation of tumor cells plays a pivotal role in osteosarcoma progression and improved stratification measures and novel anti-angiogenic strategies may benefit this specific tumor type.
Journal ArticleDOI
Recognizing and managing left ventricular dysfunction associated with therapeutic inhibition of the vascular endothelial growth factor signaling pathway.
TL;DR: An overview of LV dysfunction that can occur in patients treated with VSP inhibitors is provided, while acknowledging that currently available data specific to VSP-inhibitor LV dysfunction are limited.